Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation in the Association for Molecular Pathology (AMP) 2023
Annual Meeting and Expo with a broad range of content covering the
utility of optical genome mapping (OGM) for cell and gene therapy
and cancer research, including scientific workshops and poster
presentations from Bionano and researchers from across the genomics
landscape.
AMP’s annual meeting brings together industry, medical, and
academic professionals to discuss advances in molecular
diagnostics. The AMP conference will be held November 14-18,
2023, in Salt Lake City, Utah.
A corporate workshop session titled “Structural Variant Insights
from Adult and Pediatric CNS Tumors: Powered by Optical Genome
Mapping,” will be hosted by Dr. Chaubey, and will include a
presentation from Drs. Terraf, Kolhe, and Bornhorst on their
research regarding the role of SVs in CNS tumors. The presenters
will share data on OGM’s performance in this research application
as compared to traditional cytogenetic methods of analysis,
including microarrays. The session will take place on Wednesday,
November 15 at 12:00 PM MT in Room 250C.
A second corporate workshop session, titled “Revolutionizing
Cytogenomics with Optical Genome Mapping in Hematological
Malignancies,” will begin with a brief overview of the OGM workflow
by Dr. Hastie, followed by Drs. Ryall, Dubuc and Crocker presenting
clinical research data generated using OGM across different types
of hematological malignancies. The session will conclude with Dr.
Smith presenting an international working group initiative and
proposed framework for standardized implementation of OGM across
cytogenetic research labs. The session will take place on
Wednesday, November 15 at 1:00 PM MT in Room 250C.
As part of a session titled “Case Studies in Hematopathology,”
Dr. Nwogbo will present findings from his research using OGM to
detect significant variants in CD5 negative low-grade B-cell
lymphoma. The session will be held Friday, November 17, from 7:30-
7:45 AM MT in Room 255BC, Second Level.
Bionano leadership team members will host an Innovation
Spotlight session titled “Unlocking Easy, Fast and Scalable
Workflows for Optical Genome Mapping,”
where speakers will discuss how the OGM workflow offers
researchers a transformative technique for high-resolution,
genome-wide, comprehensive analysis of structural variation across
research in cancer and genetic disease and will highlight product
advancements and innovations. The presentation will take
place Friday, November 17, from 12:00-12:30 PM MT on
Stage 1.
In addition, 19 posters featuring results from OGM applications
in cytogenetic research will be presented at the conference. All
posters will be on display in the Convention Center, Expo Hall,
Lower Level for the duration of the conference. Odd numbered
posters will be presented November 17, from 9:15-10:15 AM MT. Even
numbered posters will be presented November 18, from 9:15-10:15 AM
MT. Posters may also be viewed here.
Scientific presentations and poster sessions from Bionano and
collaborators include:
Poster Number |
Title |
Author |
G009 |
Improved Genomic Classification in Myeloid Neoplasia Using Optical
Genome Mapping and Panel-Based NGS |
Smith A. |
H005 |
Evaluation and Comparison of Optical Genome Mapping (OGM) to
Standard of Care (SOC) Testing for Hematologic Malignancies on
Residual Flow Cytometry Samples in a Clinical Diagnostics
Laboratory Setting |
Sen S. |
H11 |
Advancing Myeloid Cancer Diagnostics with the Integrated Workflow
of NGS and NxClinical for Copy Number Analysis: Going beyond the
FISH |
Vashisht A., Kolhe R. |
H015 |
Optical Genome Mapping for Genome-Wide Structural Variation
Analysis in Hematologic Malignancies: Results of a Prospective
Study and Impact on Diagnosis and Management |
Wicks S., Sahoo T. |
H022 |
Chromoanagenesis: A Common Mechanism That Leads to Highly Complex
Karyotype and Extensive Clonal Heterogeneity in Hematological
Malignancies |
Wei Q. |
H023 |
Applying Optical Genome Mapping (OGM) to Detect and Monitor Genomic
Biomarkers in Hematologic Malignancies |
Pang A., Kim T., Chitsazan A., Hastie A. |
H038 |
Optical Genome Mapping Reveals Known and Novel Chromosome Structure
Across a Range of Hematological Malignancies in a Clinical
Setting |
Sathyanarayana S. |
H051 |
Utility, Impact, and Challenges of Integrating Optical Genome
Mapping (OGM) Technology in Routine Investigations of Hematological
Malignancies: Real-World Experience |
Singh H., Kolhe R. |
I029 |
Genome Integrity Assessment by Optical Genome Mapping for Research
in Cell and Gene Therapy, Stem Cell, and Bioprocessing
Applications |
Eastbrook J. |
ST027 |
Clinical Validation Study of a 505-Gene Panel for Variant Detection
in Diverse Solid Tumor Types |
Vashisht A. |
ST119 |
Novel Genomic Structural Variations in Angiosarcomas |
Phung T., Hastie A. |
ST143 |
Comparative Analysis of Chromosomal Microarray (CMA) and 505-Gene
Next-Generation Sequencing (NGS) Panel for Homologous Recombination
Deficiency (HRD) Phenotype Assessment in Solid Tumors |
Vashisht A., Kolhe R. |
ST147 |
Clinical Validation of NxClinical for Investigating Copy Number
Alterations (CNA) by Next-Generation Sequencing (NGS) in Solid
Tumors: A Potential Game Changer |
Gupta V., Kolhe R. |
TT026 |
Assessment of Genomic Scars Using NxClinical 6.2 Results in the
Identification of Homologous Recombination Deficient Tumors in a
Pediatric Cancer Cohort |
Lansdon L., Yoo B. |
TT028 |
Assessment of Homologous Recombination DNA Repair Deficiency (HRD)
Score Generation Using Copy Number Profiling Data from Targeted NGS
Compared to Chromosomal Microarray |
Kanagal-Shamanna R. |
TT057 |
Homologous Recombination Deficiency (HRD) Phenotype Assessment
Using Chromosomal Microarray (CMA) and 523-Gene Next-Generation
Sequencing (NGS) Panel: A Comparative Analysis |
Vashisht A., Kolhe R. |
TT058 |
Evaluation of Hi-C Sequencing as a Novel Diagnostic Technology for
Detecting Genomic and Chromosomal Structural Variants in
Constitutional Disorders |
Fang H., Liu Y. |
TT062 |
Optical Genome Mapping as Next-Generation Cytogenomic Technique in
Clinical Laboratory: A 1000 Sample Experience |
Singh H., Kolhe R. |
TT070 |
Exploring the Utility of NxClinical Software in Investigating Copy
Number Alterations (CNAs) in Myeloid Cancer Potential on
Next-Generation Sequencing (NGS): A Potential Game Changer |
Vashisht A., Kolhe R. |
Session |
Title |
Presenter/s |
Presented |
Corporate Workshop, Session 1 |
Structural Variant Insights from Adult and Pediatric CNS Tumors:
Powered by Optical Genome Mapping |
Bornhorst M., Chaubey A., Kolhe R., Terraf P. |
November 15, 202312:00-12:50 PM MTRoom 250C |
Corporate Workshop, Session 2 |
Revolutionizing Cytogenomics with Optical Genome Mapping in
Hematological Malignancies |
Crocker S., Ryall S., Dubuc A., Hastie A., Smith A. |
November 15, 20231:00-1:50 PM MTRoom 250C |
Case Study Presentation |
Variant t(2; 11)/IGK::CCND1 Rearrangement Detected by Optical
Genome Mapping in a CD5 Negative Low-Grade B-cell Lymphoma |
Nwogbo O. |
November 17, 20237:30-7:45 AM MTRoom 255 BC, Second Level |
Innovation Spotlight |
Unlocking Easy, Fast, and Scalable Workflows for Optical Genome
Mapping |
Oldakowski M., Rose, K., Jiandani, D., Saul D. |
November 17, 202312:00-12:30 PM MTStage 1 |
“We are thrilled to see a record number of presentations
featuring OGM at AMP this year,” stated Erik Holmlin, PhD,
president and chief executive officer of Bionano. “Our customers
continue to push forward cutting-edge applications in areas
including hematologic malignancy, cell and gene therapy and solid
tumor research, and we look forward to the authors sharing their
research with the AMP community.”
More details on the conference can be found here.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically identified, Bionano’s OGM products are for
research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “potential,” “will,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
OGM’s utility for research applications in hematological
malignancies, solid tumors, constitutional disorders and cell and
gene therapy, , and the utility of OGM for research in the areas
reported in the presentations given and the posters made available
at AMP’s 2023 annual meeting, and the growth and adoption of OGM
for use in research applications in hematological malignancies,
solid tumors, constitutional disorders and cell and gene therapy.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: global and macroeconomic
events, such as the impact of the COVID-19 pandemic, the ongoing
Ukraine-Russian conflict and related sanctions, and the ongoing
Israel-Hamas conflict, on our business and the global economy;
general market conditions; changes in the competitive landscape and
the introduction of competitive technologies or improvements to
existing technologies; failure of OGM to be adopted or to prove
useful for research in areas including applications in
hematological malignancies, solid tumors, constitutional disorders
and cell and gene therapy; the ability of our OGM solutions to
offer the anticipated benefits for and contributions to the areas
reported in the presentations given and posters made available at
the AMP’s 2023 annual meeting; future study results contradicting
the results reported in the presentations given and posters made
available at the AMP’s 2023 annual meeting; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts, our ability to effectively manage our uses of cash, and
our ability to continue as a “going concern”; the ability of
medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2022 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024